Skip to main
RMTI
RMTI logo

Rockwell Medical (RMTI) Stock Forecast & Price Target

Rockwell Medical (RMTI) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 31%
Hold 0%
Sell 13%
Strong Sell 6%

Bulls say

Rockwell Medical Inc. is expected to generate upwards of $10 million in net sales during the first year of a recent agreement, contributing to revenue that was not previously accounted for in projections for 2025, and will benefit from incremental price increases in subsequent years. The company is actively working to address reduced volume demand from its largest customer by pursuing new, higher-margin customer contracts and diversifying its product offerings, with several opportunities already in late-stage negotiations. Furthermore, a partnership with HydroCare for the installation of dry acid concentrate mix systems aims to enhance sales and strengthen Rockwell's position within the dialysis market.

Bears say

Rockwell Medical's outlook has been negatively impacted by a projected decline in net sales of approximately $31 million to $38 million in 2025, as its largest customer intends to reduce volumes due to a diversification of its supplier base. The company's financial forecasts have been adjusted, reflecting an anticipated revenue decrease from $107.3 million in 2025 to $87.6 million, primarily due to the loss of product volumes tied to this key customer. Additionally, historical profit margins associated with this customer's purchases have been poor, ranging from gross losses to single-digit gross margins, further contributing to the negative sentiment surrounding Rockwell Medical's financial stability.

Rockwell Medical (RMTI) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 31% recommend Buy, 0% suggest Holding, 13% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rockwell Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rockwell Medical (RMTI) Forecast

Analysts have given Rockwell Medical (RMTI) a Buy based on their latest research and market trends.

According to 16 analysts, Rockwell Medical (RMTI) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rockwell Medical (RMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.